Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury

Brain

Volumn 126, Issue 11, 2003, Pages 2497-2509

  O'Hanlon, Graham M ^a   Humphreys, Peter D ^a   Goldman, Rebecca S ^a   Halstead, Susan K ^a   Bullens, Roland W M ^d   Plomp, Jaap J ^d   Ushkaryov, Yuri ^b   Willison, Hugh J ^a,c  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d NONE

Author keywords

Anti ganglioside antibody; Calpain inhibitor; Miller Fisher syndrome; Neuromuscular junction; latrotoxin

Indexed keywords

ALPHA LATROTOXIN; CALPASTATIN; CALPEPTIN; GANGLIOSIDE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL ULTRASTRUCTURE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; EXTRACELLULAR CALCIUM; GUILLAIN BARRE SYNDROME; IMAGE ANALYSIS; IMMUNOREACTIVITY; MALE; MOTOR NERVE; MOUSE; NERVE FIBER DEGENERATION; NERVE INJURY; NEUROFILAMENT; NEUROMUSCULAR SYNAPSE; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

EID: 0142184241     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awg254     Document Type: Article

References (45)

1. Acosta JA, Benzaquen LR, Goldstein DJ, Tosteson MT, Halperin JA. The transient pore formed by homologous terminal complement complexes functions as a bidirectional route for the transport of autocrine and paracrine signals across human cell membranes. Mol Med 1996; 2: 755-65.
2. 2+-dependent vesicular exocytosis from synaptosomes. Biochimie 2000; 82: 453-68.
3. Badalamente MA, Hurst LC, Stracher A. Neuromuscular recovery using calcium protease inhibition after median nerve repair in primates. Proc Natl Acad Sci USA 1989; 86: 5983-7.
4. Badalamente MA, Hurst LC, Stracher A. Neuromuscular recovery after peripheral nerve repair: effects of an orally-administered peptide in a primate model. J Reconstr Microsurg 1995; 11: 429-37.
5. Bartus RT, Hayward NJ, Elliott PJ, Sawyer SD, Baker KL, Dean RL, et al. Calpain inhibitor AK295 protects neurons from focal brain ischemia: effects of postocclusion intra-arterial administration. Stroke 1994; 25: 2265-70.
6. Buchwald B, Weishaupt A, Toyka KV, Dudel J. Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice. Neurosci Lett 1995; 201: 163-6.
7. Buchwald B, Bufler J, Carpo M, Heidenreich F, Pitz R, Dudel J, et al. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 2001; 56: 67-74.
8. Caba E, Brown QB, Kawasaki B, Bahr BA. Peptidyl alpha-keto amide inhibitor of calpain blocks excitotoxic damage without affecting signal transduction events. J Neurosci Res 2002; 67: 787-94.
9. +-depolarized motor neuron terminals. J Neurophysiol 1999; 81: 498-506.
10. Castonguay A, Levesque S, Robitaille R. Glial cells as active partners in synaptic functions. Prog Brain Res 2001; 132: 227-40.
11. Chan SL, Mattson MP. Caspase and calpain substrates: roles in synaptic plasticity and cell death. J Neurosci Res 1999; 58: 167-90.
12. Chan SO, Runko E, Anyane-Yeboa K, Ko L, Chiu F-C. Calcium ionophore-induced degradation of neurofilament and cell death in MSN neuroblastoma cells. Neurochem Res 1998; 23: 393-400.
13. Chen Z-F, Schottler F, Lee KS. Neuronal recovery after moderate hypoxia is improved by the calpain inhibitor MDL28170. Brain Res 1997; 769: 188-92.
14. 2+. EMBO J 1998; 17: 3909-20.
15. Duchen LW, Gomez S, Queiroz LS. The neuromuscular junction of the mouse after black widow spider venom. J Physiol (Lond) 1981; 316: 279-91.
16. Glass JD, Culver DG, Levey AI, Nash NR. Very early activation of m-calpain in peripheral nerve during Wallerian degeneration. J Neurol Sci 2002; 196: 9-20.
17. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, et al. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyse muscle-nerve preparations. J Clin Invest 1999; 104: 697-708.
18. Gorio A, Rubin LL, Mauro A. Double mode of action of black widow spider venom on frog neuromuscular junction. J Neurocytol 1978; 7: 193-202.
19. Henkel AW, Sankaranarayanan S. Mechanisms of alpha-latrotoxin action. Cell Tissue Res 1999; 296: 229-33.
20. Jiang Q, Stys PK. Calpain inhibitors confer biochemical, but not electrophysiological, protection against anoxia in rat optic nerves. J Neurochem 2000; 74: 2101-7.
21. Kampfl A, Posmantur R, Nixon R, Grynspan F, Zhao X, Liu SJ, et al. mu-Calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. J Neurochem 1996; 67: 1575-83.
22. Kishi M, Fujioka T, Kurihara T. Two cases of variant type Guillain-Barre syndrome whose serum had latrotoxin-like activity. J Periph Nerv Syst 2001; 6: 152.
23. - channels. Biochem Pharmacol 1999; 57: 491-501.
24. O'Hanlon GM, Plomp JJ, Chakrabarti M, Morrison I, Wagner ER, Goodyear CS, et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 2001; 124: 893-906.
25. O'Hanlon GM, Bullens RW, Plomp JJ, Willison HJ. Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective. Neurochem Res 2002; 27: 697-709.
26. Okamoto M, Longenecker HE Jr, Riker WF Jr, Song SK. Destruction of mammalian motor nerve terminals by black widow spider venom. Science 1971; 172: 733-6.
27. Ono Y, Sorimachi H, Suzuki K. Structure and physiology of calpain, an enigmatic protease. Biochem Biophys Res Commun 1998; 245: 289-94.
28. Orlova EV, Rahman MA, Gowen B, Volynski KE, Ashton AC, Manser C, et al. Structure of alpha-latrotoxin oligomers reveals that divalent cation-dependent tetramers form membrane pores. Nat Struct Biol 2000; 7: 48-53.
29. Plomp JJ, Molenaar PC, O'Hanlon GM, Jacobs BC, Veitch J, Daha MR, et al. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol 1999; 45: 189-99.
30. Posmantur RM, Kampfl A, Siman R, Liu SJ, Zhao X, Clifton GL, et al. A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. Neuroscience 1997; 77: 875-88.
31. Rami A, Krieglstein J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res 1993; 609: 67-70.
32. Roberts M, Willison H, Vincent A, Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain-Barre syndrome and neurotransmitter release. Lancet 1994; 343: 454-5.
33. Rochon D, Rousse I, Robitaille R. Synapse-glia interactions at the mammalian neuromuscular junction. J Neurosci 2001; 21: 3819-29.
34. Roots BI. Neurofilament accumulation induced in synapses by leupeptin. Science 1983; 221: 971-2.
35. Saatman KE, Murai H, Bartus RT, Smith DH, Hayward NJ, Perri BR, et al. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci USA 1996; 93: 3428-33.
36. Schlaepfer WW. Structural alterations of peripheral nerve induced by the calcium ionophore A23187. Brain Res 1977; 136: 1-9.
37. Schumacher PA, Eubanks JH, Fehlings MG. Increased calpain I-mediated proteolysis, and preferential loss of dephosphorylated NF200, following traumatic spinal cord injury. Neuroscience 1999; 91: 733-44.
38. Squier MKT, Sehnert AJ, Sellins KS, Malkinson AM, Takano E, Cohen JJ. Calpain and calpastatin regulate neutrophil apoptosis. J Cell Physiol 1999; 178: 311-19.
39. Volynski KE, Meunier FA, Lelianova VG, Dudina EE, Volkova TM, Rahman MA, et al. Latrophilin, neurexin, and their signaling-deficient mutants facilitate alpha-latrotoxin insertion into membranes but are not involved in pore formation. J Biol Chem 2000; 275: 41175-83.
40. Wang KKW, Nath R, Posner A, Raser KJ, Buroker-Kilgore M, Hajimohammadreza I, et al. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci USA 1996; 93: 6687-92.
41. Wang MS, Wu Y, Culver DG, Glass JD. Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy. J Neuropathol Exp Neurol 2000; 59: 599-606.
42. Wells GJ, Bihovsky R. Calpain inhibitors as potential treatment for stroke and other neurodegenerative diseases: Recent trends and developments. Expert Opin Ther Patents 1998; 8: 1707-27.
43. Willison HJ, O'Hanlon GM. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol 1999; 100: 3-12.
44. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125: 2591-625.
45. Xu Y, Mellgren RL. Calpain inhibition decreases the growth rate of mammalian cell colonies. J Biol Chem 2002; 277: 21474-9.